©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Mavridis’ atrophy in Parkinson’s disease-five years later: Future perspectives
Ioannis N Mavridis, Department of Neurosurgery, “K.A.T.-N.R.C.” General Hospital of Attica, 14561 Athens, Greece
Efstratios-Stylianos Pyrgelis, Department of Neurology, “K.A.T.-N.R.C.” General Hospital of Attica, 14561Athens, Greece
Author contributions: Mavridis IN and Pyrgelis ES reviewed the literature and wrote this paper.
Conflict-of-interest: We have no conflicting interests (including but not limited to commercial, personal, political, intellectual, or religious interests) related to this work.
Correspondence to: Ioannis N Mavridis, MD, PhD, Department of Neurosurgery, “K.A.T.-N.R.C.” General Hospital of Attica, Nikis str. 2, Kifissia, 14561 Athens, Greece. pap-van@otenet.gr
Telephone: +30-697-8327199 Fax: +30-210-2833600
Received: January 18, 2015
Peer-review started: January 18, 2015
First decision: February 7, 2015
Revised: February 14, 2015
Accepted: March 5, 2015
Article in press: March 9, 2015
Published online: March 28, 2015
Processing time: 72 Days and 4.7 Hours
Peer-review started: January 18, 2015
First decision: February 7, 2015
Revised: February 14, 2015
Accepted: March 5, 2015
Article in press: March 9, 2015
Published online: March 28, 2015
Processing time: 72 Days and 4.7 Hours
Core Tip
Core tip: Mavridis’ atrophy (MA) is the nucleus accumbens atrophy in Parkinson’s disease (PD). MA begins in early-stage PD patients and is correlated with psychiatric and cognitive PD symptoms. MA is obviously part of the dopaminergic nigrostriatal degeneration that occurs in PD. It would be interesting to have a post-mortem pathological study focused on the nucleus accumbens of parkinsonic individuals. MA as an imaging finding could be a risk factor for the expression and/or severity of specific symptoms. Thus it has to be tested whether the presence of MA is related, for example, with the expression and/or severity of motor PD symptoms.